4.6 Review

NeuPSIG guidelines on neuropathic pain assessment

期刊

PAIN
卷 152, 期 1, 页码 14-27

出版社

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1016/j.pain.2010.07.031

关键词

Assessment; Autonomic nervous system; Clinical examination; Disability; Functional brain imaging; Epidemiology; Evoked potentials; Pain measurement; Microneurography; Neuropathic pain; Pain intensity; Pain quality; Psychological assessment; Quality of life; Screening tools; Skin biopsy; Somatosensory testing; Treatment efficacy; Trigeminal reflexes

资金

  1. NeuPSIG
  2. Special Interest Group on Neuropathic Pain of the International Association for the Study of Pain (IASPRegistered)
  3. Astellas
  4. Boehringer-Ingelheim
  5. EMEA
  6. GlaxoSmithKline
  7. Janssen-Cilag
  8. Lilly
  9. MSD
  10. Mundipharma
  11. Orion
  12. Pfizer
  13. Sanofi-Pasteur
  14. Grunenthal
  15. Eisai
  16. Pierre Fabre
  17. Sanofi-Aventis
  18. Cephalon
  19. NAPP Pharmaceuticals
  20. Allergan, Inc.
  21. Eli Lilly and Company
  22. Johnson Johnson
  23. Merck Co., Inc.
  24. NeurogesX
  25. Genzyme Corporation
  26. Pfizer Inc.
  27. Medtronic
  28. Eli Lilly
  29. NeurogeX
  30. Daiichi-Sankyo
  31. Merck Sharp Dohme
  32. Ratiopharm
  33. NordicDrugs
  34. Sanofi-Pasteur MSD
  35. UCB
  36. Allergan via Imperial College Consultants
  37. Astellas via Imperial College Consultants
  38. Daiichi-Sankyo via Imperial College Consultants
  39. Eisai via Imperial College Consultants
  40. GlaxoSmithKline via Imperial College Consultants
  41. Pfizer via Imperial College Consultants
  42. NeurogesX via Imperial College Consultants
  43. Spinifex via Imperial College Consultants
  44. Astellas, Inc.
  45. King Pharmaceuticals
  46. Newron Pharmaceuticals
  47. QRxPharma
  48. Schwarz-Pharma
  49. UCB Pharma

向作者/读者索取更多资源

This is a revision of guidelines, originally published in 2004, for the assessment of patients with neuropathic pain. Neuropathic pain is defined as pain arising as a direct consequence of a lesion or disease affecting the somatosensory system either at peripheral or central level. Screening questionnaires are suitable for identifying potential patients with neuropathic pain, but further validation of them is needed for epidemiological purposes. Clinical examination, including accurate sensory examination, is the basis of neuropathic pain diagnosis. For more accurate sensory profiling, quantitative sensory testing is recommended for selected cases in clinic, including the diagnosis of small fiber neuropathies and for research purposes. Measurement of trigeminal reflexes mediated by A-beta fibers can be used to differentiate symptomatic trigeminal neuralgia from classical trigeminal neuralgia. Measurement of laser-evoked potentials is useful for assessing function of the A-delta fiber pathways in patients with neuropathic pain. Functional brain imaging is not currently useful for individual patients in clinical practice, but is an interesting research tool. Skin biopsy to measure the intraepidermal nerve fiber density should be performed in patients with clinical signs of small fiber dysfunction. The intensity of pain and treatment effect (both in clinic and trials) should be assessed with numerical rating scale or visual analog scale. For future neuropathic pain trials, pain relief scales, patient and clinician global impression of change, the proportion of responders (50% and 30% pain relief), validated neuropathic pain quality measures and assessment of sleep, mood, functional capacity and quality of life are recommended. (C) 2010 International Association for the Study of Pain. Published by Elsevier B. V. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据